{
    "2021-03-07": [
        [
            {
                "time": "",
                "original_text": "业绩高增却‘杀估值’ 绩优医药股或在重构长期机遇",
                "features": {
                    "keywords": [
                        "业绩高增",
                        "杀估值",
                        "绩优医药股",
                        "长期机遇",
                        "重构"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}